Tags

Type your tag names separated by a space and hit enter

[Efficacy and safety of dapoxetine in the treatment of premature ejaculation].
Zhonghua Nan Ke Xue. 2016 May; 22(5):411-4.ZN

Abstract

OBJECTIVE

To evaluate the clinical effect and safety of dapoxetine in the treatment of premature ejaculation (PE).

METHODS

We randomly assigned 116 PE patients to receive dapoxetine on demand at 30 mg qd (dapoxetine group, n = 60, aged 23-49 years) or oral tamsulosin at 20 mg qd (control group, n = 56, aged 24-46 years). After 4 weeks of medication, we compared the clinical global impression of change (CGIC) , PE profile (PEP) scores, intravaginal ejaculation latency time (IELT) , and adverse reactions between the two groups of patients.

RESULTS

Compared with the baseline, the IELT was remarkably prolonged after treatment both in the dapoxetine group ([0.86 ± 0.17] vs [4.32 ± 2.23] min, P < 0.05) and the control ([0.88 ± 0.15] vs [4.17 ± 2.26] min, P < 0.05), with no statistically significant difference between the two groups (P > 0. 05). The post-treatment rate of CGIC in the dapoxetine group had no statistically significant difference from that in the control (85.00% vs 82.14%, P > 0.05). In comparison with pre-treatment, the patients of both the dapoxetine and control groups showed dramatically improved scores after medication in perceived control over ejaculation (0.85 ± 0.23 vs 2.13 ± 0.97 and 0.88 ± 0.21 vs 2.06 ± 0.34, both P < 0.05), ejaculation-related personal distress (1.15 ± 0.64 vs 2.89 ± 0.26 and 1.19 ± 0.53 vs 2.82 ± 0.69, both P < 0.05), satisfaction with sexual intercourse (0.81 ± 0.33 vs 2.58 ± 0.37 and 0.79 ± 0.28 vs 2.45 ± 0.32, both P < 0.05), and ejaculation-related interpersonal difficulty (2.05 ± 0.61 vs 3.24 ± 0.35 and 2.03 ± 0.65 vs 3.18 ± 0.76, both P < 0.05), with no significant differences between the two groups (P > 0.05). The incidence of adverse reactions was significantly lower in the dapoxetine than in the control group (3.33% vs 30.36%, P < 0.05).

CONCLUSION

Dapoxetine is effective for the treatment of PE, with its advantages of prolonging the intravaginal ejaculation latency time, improving the quality of sexual life, and low incidence of adverse reactions.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

chi

PubMed ID

27416664

Citation

Chen, Xiao-yu, et al. "[Efficacy and Safety of Dapoxetine in the Treatment of Premature Ejaculation]." Zhonghua Nan Ke Xue = National Journal of Andrology, vol. 22, no. 5, 2016, pp. 411-4.
Chen XY, Qu YW, Wang SG. [Efficacy and safety of dapoxetine in the treatment of premature ejaculation]. Zhonghua Nan Ke Xue. 2016;22(5):411-4.
Chen, X. Y., Qu, Y. W., & Wang, S. G. (2016). [Efficacy and safety of dapoxetine in the treatment of premature ejaculation]. Zhonghua Nan Ke Xue = National Journal of Andrology, 22(5), 411-4.
Chen XY, Qu YW, Wang SG. [Efficacy and Safety of Dapoxetine in the Treatment of Premature Ejaculation]. Zhonghua Nan Ke Xue. 2016;22(5):411-4. PubMed PMID: 27416664.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Efficacy and safety of dapoxetine in the treatment of premature ejaculation]. AU - Chen,Xiao-yu, AU - Qu,Ying-wei, AU - Wang,Suo-gang, PY - 2016/7/16/entrez PY - 2016/7/16/pubmed PY - 2016/9/16/medline SP - 411 EP - 4 JF - Zhonghua nan ke xue = National journal of andrology JO - Zhonghua Nan Ke Xue VL - 22 IS - 5 N2 - OBJECTIVE: To evaluate the clinical effect and safety of dapoxetine in the treatment of premature ejaculation (PE). METHODS: We randomly assigned 116 PE patients to receive dapoxetine on demand at 30 mg qd (dapoxetine group, n = 60, aged 23-49 years) or oral tamsulosin at 20 mg qd (control group, n = 56, aged 24-46 years). After 4 weeks of medication, we compared the clinical global impression of change (CGIC) , PE profile (PEP) scores, intravaginal ejaculation latency time (IELT) , and adverse reactions between the two groups of patients. RESULTS: Compared with the baseline, the IELT was remarkably prolonged after treatment both in the dapoxetine group ([0.86 ± 0.17] vs [4.32 ± 2.23] min, P < 0.05) and the control ([0.88 ± 0.15] vs [4.17 ± 2.26] min, P < 0.05), with no statistically significant difference between the two groups (P > 0. 05). The post-treatment rate of CGIC in the dapoxetine group had no statistically significant difference from that in the control (85.00% vs 82.14%, P > 0.05). In comparison with pre-treatment, the patients of both the dapoxetine and control groups showed dramatically improved scores after medication in perceived control over ejaculation (0.85 ± 0.23 vs 2.13 ± 0.97 and 0.88 ± 0.21 vs 2.06 ± 0.34, both P < 0.05), ejaculation-related personal distress (1.15 ± 0.64 vs 2.89 ± 0.26 and 1.19 ± 0.53 vs 2.82 ± 0.69, both P < 0.05), satisfaction with sexual intercourse (0.81 ± 0.33 vs 2.58 ± 0.37 and 0.79 ± 0.28 vs 2.45 ± 0.32, both P < 0.05), and ejaculation-related interpersonal difficulty (2.05 ± 0.61 vs 3.24 ± 0.35 and 2.03 ± 0.65 vs 3.18 ± 0.76, both P < 0.05), with no significant differences between the two groups (P > 0.05). The incidence of adverse reactions was significantly lower in the dapoxetine than in the control group (3.33% vs 30.36%, P < 0.05). CONCLUSION: Dapoxetine is effective for the treatment of PE, with its advantages of prolonging the intravaginal ejaculation latency time, improving the quality of sexual life, and low incidence of adverse reactions. SN - 1009-3591 UR - https://www.unboundmedicine.com/medline/citation/27416664/[Efficacy_and_safety_of_dapoxetine_in_the_treatment_of_premature_ejaculation]_ DB - PRIME DP - Unbound Medicine ER -